BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
Key Highlights
- ➤$13.13 million DoW award fully funds BioVie’s Long COVID study
- ➤203-patient Phase 2 ADDRESS-LC trial missed statistical significance overall
- ➤Subgroup patients with greater symptom burden showed statistically significant improvements
- ➤BioVie invited to present bezisterim Long COVID data at November NIH workshop
- ➤Bezisterim safety and tolerability were similar to placebo in the trial
Expert Statements
Penelope Markham, Senior Vice President and Program Lead for Long COVID at BioVie
“We observed a consistent and clinically coherent pattern of improvement across measures of fatigue, post-exertional malaise, clinician- and patient-reported outcomes, and objective measures of cognitive function among patients with greater baseline symptom burden”
Penelope Markham, Senior Vice President and Program Lead for Long COVID at BioVie
“These findings provide valuable insights into which patients may benefit most from bezisterim and provide an important foundation for the design of a confirmatory Phase 3 study.”
CARSON CITY, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop, hosted by the National Institute of Allergy and Infectious Diseases (NIAID) and the Foundation for the National Institutes of Health (FNIH) from November 4–5, 2026, in Bethesda, Maryland.
Dr. Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID, will share results from the Company’s Phase 2 ADDRESS-LC trial evaluating bezisterim for the treatment of the neurological symptoms of Long COVID at the “Recent Insights from Long COVID Clinical Trials” Panel Discussion on Thursday, November 5, being held from 9:10 –10:10 a.m. ET. The 2026 RECOVER-TLC hybrid workshop will provide updates on RECOVER-TLC clinical trials and emerging discoveries in Long COVID research. The event will also provide opportunities for community members to help inform future research priorities for RECOVER-TLC clinical trials.
Get started
Create a free account to read the full story.